A share price of VYNE Therapeutics Inc [VYNE] is currently trading at $1.42, down -12.35%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VYNE shares have gain 59.55% over the last week, with a monthly amount glided 45.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
VYNE Therapeutics Inc [NASDAQ: VYNE] stock has seen the most recent analyst activity on November 18, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $8.
VYNE Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.85 and $4.30. Currently, Wall Street analysts expect the stock to reach $5.75 within the next 12 months. VYNE Therapeutics Inc [NASDAQ: VYNE] shares were valued at $1.42 at the most recent close of the market. An investor can expect a potential return of 304.93% based on the average VYNE price forecast.
Analyzing the VYNE fundamentals
Trailing Twelve Months sales for VYNE Therapeutics Inc [NASDAQ:VYNE] were 0.60M which represents 106.12% growth. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -74.15%, Pretax Profit Margin comes in at -69.69%, and Net Profit Margin reading is -69.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.75, Equity is -0.72 and Total Capital is -1.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3067 points at the first support level, and at 1.1933 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6267, and for the 2nd resistance point, it is at 1.8333.
Ratios To Look Out For
To put it in perspective, the Current Ratio for VYNE Therapeutics Inc [NASDAQ:VYNE] is 4.47. In addition, the Quick Ratio stands at 4.47 and the Cash Ratio stands at 2.3. Considering the valuation of this stock, the price to sales ratio is 39.43, the price to book ratio is 0.51.
Transactions by insiders
Recent insider trading involved LEPORE PATRICK G, Director, that happened on Jan 15 ’25 when 15000.0 shares were purchased.
